Skip to main content

Table 5 Cost-effectiveness ranking

From: A trial-based cost-effectiveness analysis of antibiotic prescription strategies for non-complicated respiratory tract infections in children

 

Strategy

Cost (euros, 2022)

Incremental cost (euros)

Effectiveness (QALDs)

Incremental effectiveness (QALDs)

ICER (euros/QALDs)

NMB

Category (excluding dominated)

NAP

97.48

 

27.82

  

2189.58

DAP

100.90

3.42

27.94

0.12

28.84

2195.91

Category (all)

NAP

97.48

 

27.82

  

2189.58

DAP

100.90

3.42

27.94

0.12

28.84

2195.91

IAP

109.68

8.78

27.88

-0.06

-148.11

2182.26

  1. DAP delayed antibiotic prescription, IAP immediate antibiotic prescription, ICER incremental cost-effectiveness ratio, NAP no antibiotic prescription, NMB net monetary benefit, QALD quality-adjusted life days